In this episode of the Oncology Brothers podcast, hosts Rahul and Rohit Gosain are joined by Dr. Patrick Forde from the Johns Hopkins University to discuss the latest advancements in early stage non-small cell lung cancer. The conversation delves into treatment options for resectable and unresectable disease, including the use of neoadjuvant and perioperative therapies, as well as the role of immunotherapy in different scenarios. Dr. Forde provides insights on actionable mutations, adjuvant treatments, and the impact of targeted therapies like osimertinib and alectinib have.

Tune in to learn about the current standard of care for early stage non-small cell lung cancer and gain valuable clinical pearls from this informative discussion.

Don't miss out on this insightful episode of the Oncology Brothers podcast!

Website: http://www.oncbrothers.com/

Twitter: https://twitter.com/oncbrothers

Contact us at info@oncbrothers.com

Welcome back to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Isabel Preeshagul from Memorial Sloan Kettering Cancer Center to discuss metastatic non-small cell lung cancer treatment without actionable mutations in first-line settings.

They dive into the importance of comprehensive testing, strategies for using immunotherapy and chemotherapy combinations, and emerging second-line treatment options. Dr. Preeshagul shares insights on targeting KRAS G12C, HER2 mutation with TDXD, and the potential combination of ramucirumab with pembrolizumab.

Tune in for a detailed discussion on the latest advancements in non-small cell lung cancer treatment. Don't miss out on valuable insights from this informative episode of the Oncology Brothers podcast!

Welcome to the Oncology Brothers Podcast! Join Drs. Rahul & Rohit Gosain in this episode as they welcome Dr. Balazs Halmos, a thoracic medical oncologist from Montefiore-Einstein Comprehensive Cancer Center, to discuss the current landscape of metastatic non-small cell lung cancer with actionable mutations in first-line settings.

In this informative episode, they cover a wide range of topics including the importance of NGS testing, treatment options for various actionable mutations such as EGFR, ALK, ROS1, RET rearrangements, and more. Dr. Halmos provides valuable insights into decision-making processes, sequencing treatments, and managing toxicities associated with targeted therapies.

Don't miss out on this insightful discussion that sheds light on the rapidly evolving space of precision medicine in lung cancer treatment. Stay informed and learn how identifying and targeting specific mutations can optimize treatment outcomes and improve patient quality of life.

Tune in to the Oncology Brothers Podcast for expert insights and discussions on the latest developments in oncology.

Subscribe now to stay updated on their informative episodes!

Join the Oncology Brothers, Rahul and Rohit Gosain, in this insightful podcast episode as they dive into the world of small cell lung cancer with special guest Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson Cancer Center.

Key Points:

•⁠ ⁠The Adriatic study's impact on improving survival with Durvalumab in limited-stage disease.

•⁠ ⁠Treatment options for extensive-stage disease, including second-line therapies like Lurbinectedin and the recent approval of Tarlatamab.

•⁠ ⁠The significance of individualized treatment decisions and ongoing research in small cell lung cancer management.

In this episode, Dr. Singhi discusses the management of limited-stage small cell lung cancer, the impact of the recent Adriatic study on treatment approaches, and the use of immunotherapy in both limited and extensive-stage disease. The conversation also delves into the role of PCI, the use of Trilaciclib in extensive stage, and the recent FDA approval of Tarlatamab for small cell lung cancer.

Discover the latest advancements and treatment options for small cell lung cancer, including insights on second-line treatments, consolidation radiation, and the management of patients with driver mutations. Dr. Singhi also highlights the importance of patient advocacy groups like the Small Cell Smashers in providing support for individuals with small cell lung cancer.

Tune in to this episode for a comprehensive overview of the current treatment landscape for small cell lung cancer and gain valuable insights from Dr. Singhi's expertise in the field. Don't miss out on this informative discussion on the Oncology Brothers podcast!

Join Drs. Rohit Gosain and Rahul Gosain as they dive into the practice-changing updates from ASCO 2024 conference. In this episode, they are joined by Dr. Mark Lewis to cover key studies in GI malignancies from the conference.

In this episode, they discuss:

•⁠ ⁠The ESOPEC study comparing concurrent chemoradiation versus periop FLOT regimen for upper GI adenocarcinoma.

•⁠ ⁠The ARMANI trial on switch maintenance with ramucirumab plus paclitaxel.

•⁠ ⁠The TRANSMET trial exploring chemotherapy followed by liver transplantation for metastatic liver-confined colorectal cancer.

•⁠ ⁠The COLLISION trial comparing surgery versus ablation for small size colorectal liver metastatic disease.

•⁠ ⁠The COMMIT study looking at the use of atezolizumab with chemotherapy in first-line treatment for MSI high metastatic colorectal cancer.

These studies highlight the importance of biomarker testing and a multidisciplinary approach in the treatment of cancer.

Tune in to gain valuable insights from ASCO 2024 and stay informed about the latest advancements in oncology. Don't forget to check out their lung, GU, and breast cancer highlights from the conference as well.

Stay connected with the Oncology Brothers for more updates and discussions on the latest in the world of oncology. Thank you for tuning in!

Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Toni Choueiri, a GU Medical Oncologist from Dana-Farber Cancer Institute, to discuss key abstracts from ASCO 2024.

They delve into topics such as the impact of the EV302 study on metastatic bladder cancer, the potential role of ctDNA as a biomarker in bladder cancer, real-world data on metastatic RCC, and the PSMA-4 study in prostate cancer. The discussion covers patient-reported outcomes, treatment strategies, and the evolving landscape of oncology care.

Tune in to gain valuable insights into the latest advancements in oncology and how they are shaping the standard of care for patients. Don't miss out on this engaging conversation with experts in the field. Subscribe to the Oncology Brothers podcast for more updates from the world of oncology.

Website: http://www.oncbrothers.com/

Twitter: https://twitter.com/oncbrothers

Contact us at info@oncbrothers.com

Join the Oncology Brothers podcast as they dive into the highlights from ASCO 2024 with special guest Dr. Erika Hamilton, a breast medical oncologist from the Sarah Cannon Research Institute. In this episode, they discuss key abstracts in the world of breast cancer, including updates on RxPonder, PostMonarch, INAVO120, DESTINY-Breast06, and the Emerald Trial. Dr. Hamilton provides valuable insights on biomarker testing, CDK4/6 inhibitors, and groundbreaking advancements in HER2-targeted therapies. Discover how these studies are shaping treatment strategies for hormone receptor positive, HER2-low, and HER2-positive breast cancer patients. Don't miss out on this informative discussion packed with practical insights for community oncologists. Stay tuned for more ASCO 2024 highlights from the Oncology Brothers podcast.

Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In this episode, hosts Drs. Rahul and Rohit Gosain are joined by special guest Dr. Joshua Sabari, a thoracic medical oncologist from NYU Langone Health. Together, they dive into the highlights from ASCO 2024, focusing on key studies in lung cancer.
Here's a quick summary of what you can expect in this episode:
•⁠ ⁠LAURA Trial: Discussing the use of Osimertinib as a consolidation approach after chemoradiation in unresectable stage 3 non-small cell lung cancer patients with common EGFR mutation.
•⁠ ⁠MARIPOSA Study: Exploring the potential of Amivantamab and Lazertinib in common EGFR mutations.
•⁠ ⁠CROWN Study and other ALK inhibitors: Alectinib, Lorlatinib, and Brigatinib for metastatic non-small cell lung cancer.
•⁠ ⁠ADRIATIC Study: Examining the use of Durvalumab after concurrent chemoradiation in limited-stage small cell lung cancer.

•⁠ PALOMA-3 Trial: Discussing subcutaneous Amivantamab vs. IV Amivantamab with Lazertinib

Join the Oncology Brothers and Dr. Sabari as they break down these practice-changing studies and provide insights into the latest advancements in lung cancer treatment. Don't miss out on this informative and engaging discussion!

Stay tuned for more ASCO 2024 highlights and updates on GI, GU, and breast cancer in the upcoming episodes. Subscribe to the Oncology Brothers Podcast for the latest in oncology news and research. Thank you for listening!

Website: http://www.oncbrothers.com/

Twitter: https://twitter.com/oncbrothers

Contact us at info@oncbrothers.com